Updates in essential tremor.

Essential tremor (ET) is one of the most common tremor disorders and can be disabling in its affect on daily activities. There have been major breakthroughs in the treatment of tremor and ET is the subject of important ongoing research. This review will present recent advancements in the epidemiology, genetics, pathophysiology, diagnosis, comorbidities, and imaging of ET. Current and future treatment options in the management of ET will also be reviewed. The need for continued innovation and scientific inquiry to address the unmet needs of persons of ET will be highlighted.

Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Okelberry and Dr. Lyons have nothing to disclose. Dr. Pahwa serves as a consultant for Abbott, AbbVie, ACADIA, Acorda, Allevion, Amneal, Appello, Biogen, BioVie, CalaHealth, Convatec, Fasikl, Genetech, Insightec, Jazz, Keiferx, Kyowa, Lundbeck, Merz, Mitsubishi Tanabe, Neurocrine, Ono, PhotoPharmics, PSG, Reagenxbio, Sage, Sun Biopharma, Supernus, and UCB. He receives research support from Abbott, AbbVie, Alexza, Amylyx, Annovis, ASK Bio, Attune, Biogen, Bluerock, Bukwang, Cerevance, Cerevel, EIP, Fasikl, GemVax, Global Kinetics, Inhibikase, Intra-cellular Therapies (ITI), Jazz, Michael J Fox Foundation, Neurocrine, Neuroderm, ONO, Parkinson's Foundation, Praxis, Roche, Sage, Scion, Sun Pharma, Teva, Theravance, and UCB.

(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)